Guselkumab for inflammatory bowel disease and related joint pain
Treatments studied
Part of Bones, joints & muscles, Digestive system clinical trials.
This study tests a drug called guselkumab (Tremfya) for people who have both inflammatory bowel disease (like Crohn's or ulcerative colitis) and joint pain that may be related to arthritis (spondyloarthritis). The goal is to see if this treatment can help with both the gut and joint symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with Crohn's disease, ulcerative colitis, or an unclassified inflammatory bowel disease (IBD-U)
- You are between 18 and 75 years old
- You plan to start the study drug (Guselkumab) within the next 30 days
- You have not already been diagnosed with spondyloarthritis (SpA) before the study starts
- You have not previously taken an IL-23 inhibitor (like Stelara or Mirikizumab)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well guselkumab (Tremfya) works for people with moderate-to-severe Crohn's disease or ulcerative colitis in everyday medical practice in Italy. If you qualify, you will receive the treatment normally prescribed by your doctor and help researchers track its real-world effectiveness.
This study follows adults with moderate-to-severe Crohn's disease or ulcerative colitis who are starting treatment with guselkumab (Tremfya). It aims to see how well the medication works and how long the effects last over time.
This study tests guselkumab, a medication that reduces inflammation in the gut, for people with moderate-to-severe Crohn's disease or ulcerative colitis who haven't previously tried certain similar biologic drugs. The goal is to see how well it works and is tolerated in real-world use.
This study looks at how well guselkumab (Tremfya) works for people with moderate to severe Crohn's disease or ulcerative colitis when used in everyday medical practice. It collects information from patients who are prescribed this medicine to better understand its long-term effects and safety.
This study looks at how well guselkumab works in real life for people with moderate-to-severe Crohn's disease or ulcerative colitis. It tracks patients in the UK who start guselkumab as part of their normal care.
This study tracks how well guselkumab (Tremfya) works in real-life for people with inflammatory bowel disease in Germany. If you are starting this treatment, researchers will watch your progress and ask you to fill out simple surveys about your symptoms.
Hear when a new Spondyloarthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.